20–21 Nov 2026
Online Conference
Asia/Karachi timezone

Liposome-Based Biomaterials for Targeted Cancer Therapy and Radiotherapy

21 Nov 2026, 13:25
5m
Online Conference

Online Conference

Online Conference

Speaker

Qandeel Akram

Result

ey findings demonstrated that optimized liposomal formulations achieved an exceptional encapsulation efficiency exceeding 85%, significantly outperforming traditional free-drug delivery approaches. Furthermore, integrated radiation sensitization analysis showed a 40% reduction in required therapeutic radiation dosage levels directly at tumor sites. This dual improvement successfully minimized off-target cytotoxicity to healthy surrounding tissues by nearly 55%, validating the powerful clinical synergy between biotechnology and medical physics.

Background

Conventional cancer treatments often cause severe systemic toxicity due to low selectivity and poor targeting of healthy tissues. While nanobiotechnology offers advanced carriers like liposomes, integrating them into clinical medical physics protocols remains under-explored. There is a critical gap in optimizing lipid-based nanocarriers specifically to enhance localized radiation sensitivity while minimizing off-target adverse effects.

Discussion (methods + interpretation)

We analyzed bio-functionalized lipid bilayer vesicles utilizing advanced physicochemical characterization datasets, drug encapsulation efficiency metrics, and computational targeted delivery models. By systematically examining how liposomes exploit the enhanced permeability and retention effect alongside specific radiation interaction parameters, we interpreted their in vitro release kinetics and structural stability. The evaluated data indicates that surface-modified liposomes maintain high stability in systemic circulation while achieving precisely controlled payload release upon localized physical triggers, confirming their robust potential to seamlessly bridge biotechnology and modern medical physics protocols

Aim & Purpose

This study aimed to evaluate the efficacy of liposomal nanocarriers in co-delivering therapeutic drugs and radiosensitizers to tumor sites. This matters because improving targeted delivery maximizes radiation impact on cancer cells while protecting healthy organs, paving the way for safer, highly personalized clinical treatments.

Email address qandeelakram01@gmail.com
Phone number 03278040804

Author

Co-author

Presentation materials